Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204152887> ?p ?o ?g. }
- W3204152887 endingPage "1511" @default.
- W3204152887 startingPage "1497" @default.
- W3204152887 abstract "Abstract This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID‐19). Total (bound + unbound) and unbound imatinib plasma concentrations obtained from 134 patients with COVID‐19 participating in the CounterCovid study and from an historical dataset of 20 patients with gastrointestinal stromal tumor (GIST) and 85 patients with chronic myeloid leukemia (CML) were compared. Total imatinib area under the concentration time curve (AUC), maximum concentration (C max ) and trough concentration (C trough ) were 2.32‐fold (95% confidence interval [CI] 1.34–3.29), 2.31‐fold (95% CI 1.33–3.29), and 2.32‐fold (95% CI 1.11–3.53) lower, respectively, for patients with CML/GIST compared with patients with COVID‐19, whereas unbound concentrations were comparable among groups. Inclusion of alpha1‐acid glycoprotein (AAG) concentrations measured in patients with COVID‐19 into a previously published model developed to predict free imatinib concentrations in patients with GIST using total imatinib and plasma AAG concentration measurements (AAG‐PK‐Model) gave an estimated mean (SD) prediction error (PE) of −20% (31%) for total and −7.0% (56%) for unbound concentrations. Further covariate modeling with this combined dataset showed that in addition to AAG; age, bodyweight, albumin, CRP, and intensive care unit admission were predictive of total imatinib oral clearance. In conclusion, high total and unaltered unbound concentrations of imatinib in COVID‐19 compared to CML/GIST were a result of variability in acute phase proteins. This is a textbook example of how failure to take into account differences in plasma protein binding and the unbound fraction when interpreting PK of highly protein bound drugs, such as imatinib, could lead to selection of a dose with suboptimal efficacy in patients with COVID‐19." @default.
- W3204152887 created "2021-10-11" @default.
- W3204152887 creator A5005140861 @default.
- W3204152887 creator A5005491498 @default.
- W3204152887 creator A5014858344 @default.
- W3204152887 creator A5020883449 @default.
- W3204152887 creator A5023120816 @default.
- W3204152887 creator A5034931288 @default.
- W3204152887 creator A5043317541 @default.
- W3204152887 creator A5046328567 @default.
- W3204152887 creator A5046807019 @default.
- W3204152887 creator A5053967967 @default.
- W3204152887 creator A5062243611 @default.
- W3204152887 creator A5063675728 @default.
- W3204152887 creator A5068770247 @default.
- W3204152887 creator A5080851763 @default.
- W3204152887 creator A5082960379 @default.
- W3204152887 date "2021-10-24" @default.
- W3204152887 modified "2023-10-14" @default.
- W3204152887 title "Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study" @default.
- W3204152887 cites W1963636200 @default.
- W3204152887 cites W1963726169 @default.
- W3204152887 cites W1965356425 @default.
- W3204152887 cites W1974530971 @default.
- W3204152887 cites W1978821257 @default.
- W3204152887 cites W1984026103 @default.
- W3204152887 cites W1987045819 @default.
- W3204152887 cites W1997351962 @default.
- W3204152887 cites W2003278476 @default.
- W3204152887 cites W2017021967 @default.
- W3204152887 cites W2031630811 @default.
- W3204152887 cites W2034074778 @default.
- W3204152887 cites W2035610264 @default.
- W3204152887 cites W2044937696 @default.
- W3204152887 cites W2045194073 @default.
- W3204152887 cites W2050646947 @default.
- W3204152887 cites W2054565825 @default.
- W3204152887 cites W2055515709 @default.
- W3204152887 cites W2058734479 @default.
- W3204152887 cites W2076479050 @default.
- W3204152887 cites W2083525337 @default.
- W3204152887 cites W2083668821 @default.
- W3204152887 cites W2104899243 @default.
- W3204152887 cites W2123346471 @default.
- W3204152887 cites W2124491102 @default.
- W3204152887 cites W2135939926 @default.
- W3204152887 cites W2140111850 @default.
- W3204152887 cites W2145434855 @default.
- W3204152887 cites W2152036882 @default.
- W3204152887 cites W2154169171 @default.
- W3204152887 cites W2165902578 @default.
- W3204152887 cites W2166569409 @default.
- W3204152887 cites W2168181892 @default.
- W3204152887 cites W2171847267 @default.
- W3204152887 cites W2186582982 @default.
- W3204152887 cites W2227200581 @default.
- W3204152887 cites W2802117474 @default.
- W3204152887 cites W2806376590 @default.
- W3204152887 cites W2907814269 @default.
- W3204152887 cites W2939463022 @default.
- W3204152887 cites W2945075428 @default.
- W3204152887 cites W2951603477 @default.
- W3204152887 cites W3037636192 @default.
- W3204152887 cites W3041137934 @default.
- W3204152887 cites W3080260365 @default.
- W3204152887 cites W3124815682 @default.
- W3204152887 cites W3127115635 @default.
- W3204152887 cites W3127420938 @default.
- W3204152887 cites W3150010507 @default.
- W3204152887 cites W3157777308 @default.
- W3204152887 cites W3168338972 @default.
- W3204152887 cites W3204152887 @default.
- W3204152887 cites W4232087861 @default.
- W3204152887 cites W656665617 @default.
- W3204152887 doi "https://doi.org/10.1002/psp4.12718" @default.
- W3204152887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34608769" @default.
- W3204152887 hasPublicationYear "2021" @default.
- W3204152887 type Work @default.
- W3204152887 sameAs 3204152887 @default.
- W3204152887 citedByCount "7" @default.
- W3204152887 countsByYear W32041528872021 @default.
- W3204152887 countsByYear W32041528872022 @default.
- W3204152887 countsByYear W32041528872023 @default.
- W3204152887 crossrefType "journal-article" @default.
- W3204152887 hasAuthorship W3204152887A5005140861 @default.
- W3204152887 hasAuthorship W3204152887A5005491498 @default.
- W3204152887 hasAuthorship W3204152887A5014858344 @default.
- W3204152887 hasAuthorship W3204152887A5020883449 @default.
- W3204152887 hasAuthorship W3204152887A5023120816 @default.
- W3204152887 hasAuthorship W3204152887A5034931288 @default.
- W3204152887 hasAuthorship W3204152887A5043317541 @default.
- W3204152887 hasAuthorship W3204152887A5046328567 @default.
- W3204152887 hasAuthorship W3204152887A5046807019 @default.
- W3204152887 hasAuthorship W3204152887A5053967967 @default.
- W3204152887 hasAuthorship W3204152887A5062243611 @default.
- W3204152887 hasAuthorship W3204152887A5063675728 @default.
- W3204152887 hasAuthorship W3204152887A5068770247 @default.
- W3204152887 hasAuthorship W3204152887A5080851763 @default.